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Inhibition of Thrombin-Catalyzed Reactions in
Blood Coagulation and Platelet Activation by Heparin Fractions
in the Absence of Antithrombin III
Dominique Baruch, Theo Lindhout, Rob Wagenvoord, H. Coenraad Hemker
Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
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Abstract. The antithrombin-Ill-independent effect of heparin was studied in the following
thrombin-catalyzed reactions: activation of purified plasma factor V and partially purified
plasma factor VIII:C, generation of factor Vu from the platelets and, in the presence of colla-
gen, of the platelet procoagulant activity. Five heparin fraclions and a heparinoid were com-
pared to crude heparin. Crude heparin was a more potent inhibitor of these reactions than the
fractions or the heparinoid. The inhibitory action of heparin (fractions) appeared to be the
result of the formation of a complex between heparin and thrombin that alters the specihcity
of thrombin towards high molecular weight substrates. The inhibition of these thrombin-
dependent feedback reactions in blood coagulation might be of importance in the mechanisms
for the dissociation between the antithrombotic and hemorrhagic properties of low molecular
weight heparins.
Introduction
Heparin is one of the most important
drugs for the treatment and prevention of
venous thrombosis and thromboembolism.
However, it still presents many puzzling
questions on diflerent levels to clinicians and
clinical chemists, biologists, biochemists and
certainly not least for the pharmaceutical in-
dustry. Clinicians and clinical chemists know
that the major drawback to the therapeutical
use of heparin is the absence of any reliable
laboratory test to keep the patient in the nar-
row range that ensures an efficient anti-
thrombotic action but will not cause a hem-
orrhagic tendency. From the literature it is
evident that the properties ofheparin to cat-
alyze factor X" and/or thrombin inactivation
by antithrombin III do not suffrciently reflect
the complexity of in vivo heparin actions.
Research over the last few years has led to the
development of heparin fractions of known
compositions which allowed considerable
progress in understanding the structure-func-
tion relationships. Our contribution, as bio-
chemists of blood coagulation, is to identify
the complete spectrum of heparin-sensitive
reactions, to develop a relevant in vitro de-
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termination of the action of heparin and to
establish their correlation with in vivo ef-
fects.
As thrombin formation is the central pro-
cess in hemostasis and thrombosis, the inhi-
bition by heparin of thrombin formation has
been our main focus of interest. It should be
appreciated that heparin can inhibit throm-
bin by 2 separate mechanisms, i.e. the anti-
thrombin activity can be either antithrom-
bin-Ill-dependent or -independent.
Thrombin Generation and Feedback
Mechanisms
The mechanisms leading to thrombin for-
mation are, on the one hand, a series of
proenzyme activation reactions (factor VII ->
factor X -+ factor II) and on the other hand
interactions at a phospholipid-solute inter-
phase []. Procoagulant, negatively charged
phospholipids are provided by the mem-
brane of activated platelets and wounded
cells [2]. The assembly of an enzymatic com-
plex at the phospholipid surface is completed
by the presence of non-enzymatic protein co-
factors (respectively tissue factor, factor VIII.
and factor V") [3-5]. The interaction of
thrombin and platelets is a complicated
process. Thrombin once formed in trace
amounts governs a set of positive feedback
reactions. Thrombin is a potent platelet acti-
vator and induces the release reactions by
which factor V becomes available. Platelet
factor V seems to contribute more to throm-
bin generation and hence to hemostasis and
coagulation than plasma factor V does. This
was demonstrated within a group of factor-
V-deficient patients, where the severity of
bleeding was shown to depend on the platelet
rather than on the plasma factor V deficiency
[6]. Thrombin also converts factor V and fac-
tor VIII into their activated forms. Together
with collagen, thrombin generates the ap-
pearance of a procoagulant surface at the
outer membrane of the platelets [2]. If the
thrombin formation were not controlled by
natural inhibitors and regulatory processes
(such as inactivation of factors Vu and VIII.
by activated protein C), these coagulation
factors and platelet interactions would result
in an explosive thrombin formation.
The Antithrombin- I I I - Dependent Action
of Heparin
The main anticoagulant function of hepa-
rin is to enhance the inactivation ofthe serine
proteases of blood coagulation (thrombin,
factor X", IXu, XI" and XII) by antithrom-
bin III (AT IID. Three models are currently
described. (a) Heparin binds to AT III, in-
ducing a conformational change [7, 8]; (b) the
reactivity of thrombin with AT III is en-
hanced by the binding of heparin to throm-
bin [9, l0]; and (c) a ternary complex is
formed and stabilized by the interaction of
AT III and thrombin with heparin, the so-
called template model I l-13]. These models
are no1 mutually exclusive.
Factor X" inactivation by the heparin-AT
III complex is accounted for by the interac-
tion of factor X" with AT III and not by the
interaction of factor Xu with heparin bound
to AT III. Factor XII" is inhibited in the
same way. The saccharide structure required
to potentiate the inactivation of factor X"
and factor XII" is contained within the AT-
Ill-binding region [4]. Heparin fractions
with a molecular weight higher than 3,400
are equally active [5]. On the contrary,
thrombin and factors IXu and XIu can bind to
the heparin molecule as well as to the AT III
molecule. The potency of heparin in caralyz'
ing the AT III thrombin reaction increases
with the molecular weight of heparin [l6]. At
Antithrombin-III-Independent Eflect of Heparin
high concentrations, heparin has an addi-
tional effect by catalyzing the inhibition of
thrombin by heparin cofactor II [7].
However, because thrombin formation is
a phospholipid-bound process, the inactiva-
tion ofthe serine proteases ofblood coagula-
tion has to be considered as it occurs at the
phospholipid-solute interphase, where the
enzyme is located when it is physiologically
active, rather than on the free enzyme. It has
already been known for several years [18, l9]
that factor X" bound to phospholipids is
much less accessible to the inactivation by
AT Ill-heparin than free factor Xu is. This
was recently demonstrated to be also the case
when factor X" and factor Vu bind to acti-
vated platelets, therefore requiring that these
complexes are cleared from blood before the
heparin therapy can be eflective 120,211.
T he A nt it hr o mbi n- I I I - I ndep e nde nt Effe ct
of Heparin
Evidence for an AT-Ill-independent eflect
of heparin in reactions of blood coagulation
and hemostasis is three-fold.
(l) Some heparin fractions with a low
affrnity for AT III, which are virtually devoid
of any antithrombin or antifactor X" activity
in vitro significantly increased hemorrhage
without influencing the in vivo antithrom-
botic effect in animal experimental models
[22]. Furthermore this low affrnity heparin
fraction potentiated the antithrombotic ac-
tion of a high affrnity heparin oligosaccharide
of a molecular weight lower than 3,500 which
only had an antifactor Xu activity in vitro [23].
(2)In a system consisting ofpurified coag-
ulation factors and synthetic phospholipids,
heparin can inhibit prothrombin and factor
X activation. This effect was attributed to
the deplacement of the bound proteins from
the phospholipid surface 124-261. However,
these experimental results can alternatively
be explained by an effect of heparin on the
thrombin-catalyzed factor VIII activation.
As the effect of heparin in these experiments
was practically abolished if the activated fac-
tor VIII was present, the latter explanation
seems more probable. Also the fact that in an
AT-Ill-depleted plasma the effect of heparin
on the inhibition of factor Xu or thrombin
generatioir is almost negligible, supports this
notion [27]. Comparison of crude heparin
and low affrnity heparin in prothrombin acti-
vation in AT-Ill-depleted plasma showed
that the inhibitory effect of both heparins was
similar. These experiments do not exclude an
eflect due to other serine protease inhibitors.
No further insight was brought in the mecha-
nism underlying the deplacing effect by hepa-
rin of protein-lipid interactions [28].
(3) Conflicting data have been reported
showing that heparin either induced [29] or
inhibited platelet aggregation [30]. It was
shown that some of the heparin effects were
related to an interaction with platelet func-
tions [31]. Bleeding caused by heparin has
been attributed to a direct effect on platelets.
The original observation of Salzman et al.
[32] that high molecular weight, low AT III
affinity heparin fractions, were more reactive
on platelets than low molecular weight, high
AT III affinity fractions, suggested a correla-
tion between the hemorrhagic eflect of hepa-
rin and the anticoagulant properties in vitro.
However, this correlation is far from being a
strong one [33].
In this study, we show that an AT-III-
independent effect ofheparin in blood coagu-
lation and platelet reactions might be the
result of an interaction between thrombin
and heparin. To this end, we used purified
proteins, synthetic phospholipids or washed
platelets under well defined kinetic condi-
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tions, together with different heparin frac-
tions of known antithrombotic/hemorrhasic
properties 134-311.
Materials and Methods
Experimental procedures for protein and phospho-
lipid preparation as well as platelet isolation are as
described earlier [38]. Purification of bovine factor
VIII:C was performed by diflerential precipitation by
polyethylene glycol. The determination of the platelet
factor Vu generation upon the addition of thrombin,
and of the platelet procoagulant activity in the pres-
ence ofthrombin and collagen, has been reported pre-
viously [38].
Heparin Fractions
We were interested in measuring the effect of hep-
arin fractions that had already been used in clinical
trials and in vivo animal experimental models [34-
371. They were supplied by the following laboratories:
Choay Institute (CY 216, an ethanol precipitation
fragment; CY 222, a fragment obtained by nitrous acid
depolymerization), Pharmuka Laboratories (FF
32038, a crude heparin; PK 10169. obtained by con-
trolled depolymerization; EMT 966, EMT 967, ob-
tained by gel filtration of PK 10169) and Organon
Laboratories (crude heparin and Org 10172, a sul-
phated mucopolysaccharide). The average molecular
weights, antifactor X, and antithrombin activities are
listed in table I.
PuriJied Plasma Factor V Activation
Bovine factor V (100 nM) was incubated for 5 min
at 37 " C in the presence of 3 mM CaCl2. The reaction
was started by the addition of thrombin (usually 0.3
nM). Aliquots were taken in time, diluted l:1,000 in
buffer containing 50 mM Tris, 175 mM NaCl, 5 mM
CaCl2 and 0.5 mg/ml HSA, pH 7.9. Factor Vu activity
was measured as previously described [38].
Partially Purified Factor VIII:C Activation
Partially purified factor VIII:C was activated by
bovine thrombin in the following way: factor VIII:C
(20 1tl, 27 U/ml) was incubated in I ml Michaelis
buffer containing29 mM sodium barbiturate,29 mM
sodium acetate and I l6 mMNaCl, pH 7.3. The reac-
tion was started with the addition of thrombin (3 nM).
Table I. Characteristics of heoarin fractions
Compound Mean Anti Xu Anti II
molecular act ivi ty acl ivi ty
weight U/mg U/mg
Crude
heparin
FF 32038
Org 10172
CY 216
CY 222
P K  1 0 1 6 9
EMT 966
EMT 967
15,000
15,000
6,400
4,500
2,500
4,500
6,500
3,300
175
1 6 5
0.32
l0-20
5 -15
30
70
0
175
1 6 5
8
200
250
120
160
100
Aliquots (10 pl) of a factor-Vlllu-containing sample
were added to the clotting assay containing 60 pl fac-
tor-Vlll-defrcient plasma, 4 nM factor IX", 50 F,l./
phospholipid [(250lo phosphatidylserine (PS), 75olo
phosphatidylcholine (PC)l and l0 mM CaCll The
clotting time was recorded on an automatic coagulom-
eter. A calibration curve was established with normal
pool plasma activated with 9 nM thrombin in order to
determine the amount of factor VIII' present in the
sample.
Inhibilion Studies
The assessment of a heparin effect on thrombin-
catalyzed reactions can be made provided that the fol-
lowing conditions are met.
(l) Thrombin formation by the prothrombinase
complex can be measured as a function of varying con-
centrations of an accessory component (factor Vu or
phospholipids) under the conditions where the acces-
sory component under investigation is the only rate-
limiting factor of the reaction. Factor VIIIa can be
determined in a clotting assay in a cornparable man-
ner.
(2) An effect of heparin on a thrombin-catalyzed
reaction can be assessed if the manner in which this
reaction depends on the thrombin concentration is
known. This is shown, in frgure l, for the thrombin-
catalyzed factor VIII activation and in figure 2 for the
thrombin-catalyzed factor V activation. Throughout
this study, excess thrombin concentrations were
avoided in order to be able to quantitate the heparin
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effects. We previously showed that a similar relation-
ship exists in the thrombin-catalyzed platelet V" gen-
eration and thrombin-plus collagen-induced platelet
procoagulant activity [38].
(3) The interaction between heparin and thrombin
results in the formation of a l : l  complex. This com-
plex formation leaves unaflected the catalytic site of
thrombin towards the synthetic chromogenic sub-
strate, but has an altered enzymatic activity towards
macromolecular substrates. In contrast with others
[39], we found that heparin and heparin lractions up to
200 pg/ml had no effect on the catalytic efficiency of'
thrombin on the chromogenic substrate 52338 when
the substrate concentration is above or near the K.
(data not shown).
Upon the formation of a heparin-thrombin com-
plex, the inhibition of the thrombin activity on its
macromolecular substrate results in a decrease in the
rate of the thrombin-catalyzed reaction. The IC5s is
the heparin concentration required to obtain half-
maximal reaction velocity. The IC56 values can be
o.? o 3 0.4
T h r o m b i n { n M )
accurately determined by a plot ofthe reciprocal total
heparin concentration versus the ratio vol(vo-v),
where vo and v are the velocities ofthe reaction in the
absence and the presence of heparin, respectively.
Results and Discussion
Demonstration of the Absence of
Interaction of Heparin with Other
Components than Thrombin
Before we could attribute to heparin the
observed effects on the thrombin-catalyzed
reactions, we had to exclude any effect of
heparin carried over into the assay mixtures.
Therefore, as an effect ofheparin on the pro-
tein-phospholipid interaction has been re-
ported [22], we had to estimate the effect of
0.1
Fig. 1. Dependency of the lactor VIII activation on thrombin concentralion. Normal plasma is incubated at
37'C with varying bovine thrombin concentrat ions for l5 s. A sample is brought to the lactor X acrivation
mixture containing phospholipids vesicles (250/o PS/75ok PC, 5X l0-5 M), CaCl2 ( l0mM) and facror IXu(4.0x l0-e M).The rate of lactor X activation is measured after 2 and 4 min. The results are expressed as rate of
the factor Xu lormation per minute per unit factor vlllu present in I ml plasma.
Fig. 2. Dependency of factor V activation on thrombin concentration. Purified bovine factor V 000 nM) was
incubated for 5 min at 37 'C in a buffer containing 50 mM Tris, 175 mM NaCl, 3 mM CaCl2, 0.5 mg human
serum albumin/ml in the presence of varying thrombin concentrations. Factor Vu activity was delermined as
described in 'Materials and Methods'.
.
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heparin on separate protein-lipid interac-
tions. This was done by use of a protein-lipid
equilibrium technique according to van de
Waart et al. [40]. Factor X" (0.1 1tM), factor
V" (0.1 ytM) or prothrombin (0.05 pM) were
incubated with large volume phospholipid
vesicles, 25 pM (200/o PS - 80o/o PC), in 50
mM Tris, 100 mM NaCl, pH 7.5, at 20"C.
After centrifugation for 30 min at 30,000 g at
20"C, the concentrations of the bound pro-
teins were estimated by determination of the
remaining activity in the supernatant (factor
Xu was determined on 52337, factor V" by
the factor Vu assay and prothrombin after
activation by Echis carinatus venom coagu-
lant). Both heparin FF 32038 and PK 10169
at a final concentration of 0.5 mglml could
not displace factor Vu, factor Xu or pro-
thrombin from the phospholipid surface. The
concentrations ofbound protein in the pres-
ence and absence ofheparin (fraction) were:
0.02 W,0.10 pM, 0.03 pM for factor Xu,
factor V" and prothrombin, respectively.
The effect of heparin on the thrombin-cat-
alyzed factor VIII activation is measured in a
clotting assay using a factor-Vlll-deficient
plasma; therefore heparin is carried over and
indeed influences the clotting times. This
problem is circumvented by making a cali-
bration curve for the factor VIII. formation
in the presence of the same amounts of hepa-
rin as those that are carried over. In that way,
heparin does not affect the relative changes
occurring during the thrombin -catalyzed fac-
tor VIII activation. In all other studies, we
used a completely purihed system, in which
no effect of heparin carried over into the
assay was observed. This was demonstrated
by letting the substrate of thrombin be fully
activated in the absence ofheparin and add-
ing a high heparin concentration imme-
diately before transferring a sample to the
measuring system. No effect of heparin or
heparin fractions at final concentrations of
up to 0.5 mglml was observed after a l0-min
incubation, showing that the amount of
thrombin-activated substrate was indepen-
dent ofthe presence ofheparin in the activa-
tion mixture. This demonstrates that heparin
did not interfere with the assembly or the
functioning of the prothrombinase complex.
In the reactions where platelets are in-
volved, we had to rule out the presence of AT
III in the washed platelet preparations [41].
This was done by incubation ofwashed plate-
let suspension (107/ml) with 5 nM thrombin
in the presence of heparin (fractions) (10
pglml).After 20 min, the amidolytic activity
of thrombin appeared to be unaffected. In
order to discriminate between an effect of
heparin on the thrombin-induced factor Vu
generation and an eflect related to the bind-
ing of heparin to platelets, we measured the
eflect of heparin on the beta-thromboglobu-
lin release, induced by either thrombin or
collagen. Only the thrombin-induced release
of beta-thromboglobulin was aflected by
heparin (900/o inhibition of the release reac-
tion at 50 pg heparin/ml), showing that the
reaction was occurring between thrombin
and heparin and was not due to an efTect of
heparin on platelets.
Effect of Heparin (Fractions) on the
Thrombin- Catalyzed Plasma Factor VIII
Activation
We used a semi-quantitative stimation of
the effect of heparin on the thrombin-cata-
lyzed factor VIII activation. Figure 3 shows
the time course of the factor VIII activation
in the absence and presence of varying
amounts of unfractionated heparin (FF
32038). Heparin has an effect both on the ini-
tial rate of the factor VIII activation and on
Antithrombin-III-lndeoendent Effect of Heoarin
Fig.3. Effect of crude heparin FF 32038 on the
thrombin-catalyzed lactor VIII activation. Isolated
factor VIII:C was incubated with thrombin (3 nM\
and varying concentrations of heparin FF 32038. o =
No heparin; o = 0.14 pglml; r = 0.70 pglml; a = 1.43
pglml; I = 2.9 pg/ ml n = 5.'7 pg/ ml. At timed intervals,
factor Vlllu-containing samples were transferred to
the assay. Factor VIII, was determined by using a cal-
ibration curve established with normal plasma as de-
scribed in 'Materials and Methods'.
the rate of inactivation of factor VIII.. It was
observed that the level offactor VIIIa after 4
min was in all cases lower in the absence than
in the presence of heparin. This stabilizing
effect of heparin could be due to an effect
either on thrombin, and/or on the factor
VIII,. Further experiments are required for a
better understanding. We estimated the effect
on the initial rate of activation, of heparin FF
32038, PK 10169 and Org 10172(f ig.4).  The
IC5e values were found to be 0.5 pg/ml,1.75
pglml and 25 14/ml, respectively.
Effect of Heparin (Fractions) on the
Thrombin- Catalyzed P lasma Factor V
Activation
Bovine factor V (100 nM) was incubated
at 3l "C with calcium (3 mM) and varying
concentrations of heparin (fractions). The
reaction was initiated by the addition of
thrombin (0.3 nM). After 6 min, 1:1,000
diluted samples were assayed for the factor
Vu activity. The percentage of the residual
factor V" concentration was plotted as a func-
tion of the heparin concentration (hg. 5). De-
termination of the IC5s values was performed
by use of the double reciprocal plot as de-
scribed above (fig 5, inset). It is clear that
unfractioned heparin is a more efficient in-
hibitor (IC50 = l0 pglml) than the fractions
CY 216 (IC50 = 25 pg/ml), CY 222 (IC = 25
pglml) or the heparinoid Org 10172 (IC50 =
125 pg/ml). The IC5s values of EMT 966,
EMT 967 and PK 10169 were 28 pg/ml,12.5
pglml and 62.5 pg/mI, respectively.
Effect of Heparin Fractions on the
Thrombin-Induced Platelet Factor Vo
Generation and on the Thrombin-plus
Collagen-I nduced Platelet Procoagulant
Activity
We have previously described a direct in-
hibitory eflect of heparin on thrombin in
platelet activation [38]. We tested the effect
of heparin on the thrombin-induced platelet
factor Vu generation and on the thrombin-
plus collagen-induced platelet procoagulant
activity. We have extended the previous
study to the effect ofother heparin fractions,
PK 10169 and 2 fractions obtained by gel fil-
tration of PK 10169: EMT 966 and EMT
961 . The results of these studies are depicted
c
=
f.;t
d5
act iva t ion  t ime,  min
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Fig.4. Effect ofheparin (fractions) on the initial rate ofthe thrombin-catalyzed factor VIII activation. Factor
VIII:C was incubated with thrombin in the presence of varying amounts of heparin. The initial rate of the fac-
tor VIII  act ivat ion was measured at 30 s as described in the legend to f igure 3. ao= FF 32038, o = PK 10169.
b o =  O r e  1 0 1 7 2 .
Fig.5. Effect of heparin on the initial rate of the
thrombin-catalyzed lactor V activation: factor V (100
nM) was activated for 5 min by thrombin (0.3 nM) in
the presence of CaClz Q mM) and varying concentra-
t ions ofheparin. o = Crude heparin; o = CY 216; t  =
CY 222; I = Org 10172. Factor Vu activity was deter-
mined as explained in 'Materials and Methods'.
4{J b0 w 1u{}
heparin, pglml
in table II. Whereas in the platelet factor Vu
generation the IC5s values are very similar
(+ 20 pe/ml), there are striking differences
for the procoagulant activity of thrombin-
plus collagen-activated platelets. Heparin FF
32038 inhibited the thrombin-plus collagen-
induced procoagulant activity with an IC5s of
2 pg/ml, whereas much higher concentrations
of PK 10169 and EMT 967 would be re-
quired to obtain the same extent of inhibi-
tion.
Conclusions
From in vitro studies we have been able to
demonstrate a direct inhibitory effect of hep-
arin on several thrombin-dependent reac-
tions in blood coagulation. An AT-III-inde-
pendent effect of heparin is shown on the
thrombin-calalyzed factor VIII activation.
heparin,;rg/ml
:€
:F.
l : : lJ
:tt:
o
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FF 32038
PK 10169
EMT 966
EMT 967
Table Il. Effect of heparin on the thrombin-in-
duced platelet factor Vu generation and on the thrombin-
plus collagen-induced platelet procoagulant activity
Compound IC:o 0tg/ml)
factor Vu procoagulant
generation activity
sity of heparin is independent of the a{Iinity
for AT III, but correlates with the thrombin-
binding 1421, and a recent report describes
that the surface charge as well as the surface
charge density of heparin [43] is important in
thrombin-binding.
Sulphatation seems to be an important
parameter for the nonspecifrc binding of
polysaccharides to various proteins. This not
only holds for the heparin-protease interac-
tion, but also for the inhibiting action of pen-
tosane polysulphate [44], recently shown to
be caused by inhibition of the thrombin-
induced factor VIII:C activation lWagen-
voord, unpublished resultsl. Also the interac-
tion of heparin fractions with endothelium is
seen to be strongly dependent upon the de-
gree of sulphatation fBarzu, personal com-
munication]. Further studies are required to
better characterize the in vivo signihcance of
this effect, as to the dissociation between
antithrombotic and hemorrhagic effect of
low molecular weight heparin fractions. Inhi-
bition by heparins ofthe feedback activation
reactions of thrombin by a process indepen-
dent of AT III anyhow seems to be one of the
mechanisms by which heparins modulate the
thrombin formation and hence hemostasis
and thrombosis.
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